At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
02197 CLOVER BIO-B
Market Closed 04-02 16:08:19
2.850
+0.000
0.00%
High3.040
Low2.790
Vol10.73M
Open2.830
D1 Closing2.850
Amplitude8.77%
Mkt Cap3.70B
Tradable Cap3.70B
Total Shares1.30B
T/O31.40M
T/O Rate0.83%
Tradable Shares1.30B
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Loading ...
Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
Clover Bio clarifies Gavi settlement terms, caps future payments at US$58 million
Clover Biopharmaceuticals Ltd is an investment holding company primarily engaged in the research and development, manufacture and commercialization of innovative vaccines. The Company’s products and candidates include Respiratory Syncytial Virus (RSV) Vaccine (SCB-1019), seasonal quadrivalent influenza vaccine AdimFlu-S, SCB-219M, COVID-19 Vaccine and others. The Company leverages the Trimer-Tag technology platform to conduct research and development (R&D) for innovative vaccines that can fulfill unmet need, with a focus on building a respiratory vaccine franchise and establishing a presence in the pediatric vaccine market. The Trimer-Tag is a product development platform for the creation of protein-based vaccines based on naturally trimerization-dependent targets. The Company conducts its business in the domestic and overseas markets.